Skip to main content
. 2020 Jul 7;12(7):1820. doi: 10.3390/cancers12071820

Figure 4.

Figure 4

Variation in levels of each target miRNA by response to NACT was assessed in the four breast cancer subtypes. (A) miRNA-21 patients with low levels had a higher response rate in Luminal cancers. (B) miRNA-145 patients with low levels had a higher response rate in Luminal cancers. Luminal (responders n = 15, non-responders n = 41), Luminal B Her2 (responders n = 12, non-responders n = 7), Her2+ (non-luminal) (responders n = 10, non-responders n = 3), Triple negative (responders n = 14, non-responders n = 9). p < 0.05 considered significant.